The European Patent Office grants patent for tasquinimod for treatment of multiple myeloma
(Thomson Reuters ONE) -
Lund January 9, 2017 - Active Biotech AB (Nasdag Stockholm: ACTI) announces
today that the European Patent Office has decided to grant Active Biotech's
patent application covering tasquinimod for use in the treatment of multiple
myeloma. The patent will be granted as European Patent No. 3041472 on February
1, 2017 and has a duration lasting until 2035.
For further information, please contact:
Tomas Leanderson, President & CEO Active Biotech AB
Tel: +46 46 19 20 95 (Org.nr 556223-9227)
Box 724, 220 07 Lund
Hans Kolam, CFO Tel: +46 46 19 20 00
Tel: +46 46 19 20 44
About tasquinimod
Tasquinimod is an immunomodulatory, anti-metastatic and anti-angiogenic compound
that affects the tumor's ability to grow and spread. The development of
tasquinimod has previously been focused on the treatment of prostate cancer with
clinical proof of concept and a good safety profile shown in Phase 2 and 3
studies. Tasquinimod's mechanism of action is broadly applicable as anti-tumor
treatment and very good results have been achieved in models for multiple
myeloma, a blood cancer with a high medical need. Active Biotech is seeking a
partner for the continued development of tasquinimod in multiple myeloma.
Active Biotech AB (publ) (Nasdag Stockholm: ACTI) is a biotechnology company
with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory properties, is
in pivotal Phase 3 development for the treatment of relapsing remitting multiple
sclerosis. Also, laquinimod is in Phase 2 development for the treatment of
primary progressive multiple sclerosis and Huntington's disease. Furthermore,
commercial activities are conducted for the tasquinimod, paquinimod and SILC
projects. Please visit www.activebiotech.com for more information.
This information is information that Active Biotech AB is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out above, at 13.00 pm
CET on January 9, 2017.
The European Patent Office grants patent for tasquinimod for MM:
http://hugin.info/1002/R/2069704/777561.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Far Intersects 23m of 1.10% Li2O from Initial Drilling on Zoro Lithium Property, ManitobaDatum: 09.01.2017 - 13:00 Uhr
Sprache: Deutsch
News-ID 516490
Anzahl Zeichen: 2946
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 134 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"The European Patent Office grants patent for tasquinimod for treatment of multiple myeloma"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
